Literature DB >> 14759498

Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.

Jennifer M Kulak1, Jay S Schneider.   

Abstract

We studied [(125)I]alpha-bungarotoxin (btx) binding to alpha7 nicotinic acetylcholine receptors in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposed macaque monkeys. [(125)I]alpha-Btx binds throughout the normal monkey brain, with the greatest density in the thalamic nuclei and with moderate to low binding in the hippocampus, prefrontal cortex, caudate, putamen, and substantia nigra. Chronic administration of low doses of MPTP resulted in animals with stable cognitive deficits without overt parkinsonian motor symptoms. [(125)I]alpha-Btx binding in the brains of these animals was significantly increased in the outermost layers of the supplementary motor cortex (area 6M, approximately 50%), primary motor cortex (area 4, approximately 112%) and throughout the putamen (approximately 50-72%). In contrast, there was no change in [(125)I]alpha-btx binding in the brain regions thought to be involved in mediating the cognitive functions impaired in these monkeys (e.g., the hippocampus, areas 9/46D and 46D of the principal sulcus, and area 24c of the cingulate sulcus). Animals with cognitive dysfunction that received escalating doses of MPTP for >6 months developed motor signs of parkinsonism which were indistinguishable from those seen in animals rendered acutely parkinsonian with short term administration of large doses of MPTP. These two "motor symptomatic" groups had significantly increased [(125)I]alpha-btx binding only in the dorsolateral putamen. Immunohistochemical studies showed that the increased [(125)I]alpha-btx binding, when observed, was associated with enhanced immunohistochemical staining localized to neurons and was not a result of an astrocytic response to MPTP. These results suggest that the increase in alpha7 nicotinic acetylcholine receptor expression in the chronic low-dose MPTP treated, motor asymptomatic monkeys may be a part of compensatory processes contributing to the maintained motor functioning in these animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759498     DOI: 10.1016/j.brainres.2003.10.062

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.

Authors:  Sung Won Kim; Yu-Shin Ding; David Alexoff; Vinal Patel; Jean Logan; Kuo-Shyan Lin; Colleen Shea; Lisa Muench; Youwen Xu; Pauline Carter; Payton King; Jasmine R Constanzo; James A Ciaccio; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2007-07       Impact factor: 2.408

2.  Synthesis and evaluation of new radioligands [(11)C]A-833834 and [(11)C]A-752274 for positron-emission tomography of α7-nicotinic acetylcholine receptors.

Authors:  Andrew G Horti; Hayden T Ravert; Yongjun Gao; Daniel P Holt; William H Bunnelle; Michael R Schrimpf; Tao Li; Jianguo Ji; Heather Valentine; Ursula Scheffel; Hiroto Kuwabara; Dean F Wong; Robert F Dannals
Journal:  Nucl Med Biol       Date:  2013-01-05       Impact factor: 2.408

3.  Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy.

Authors:  Dean F Wong; Hiroto Kuwabara; Martin Pomper; Daniel P Holt; James R Brasic; Noble George; Boris Frolov; William Willis; Yongjun Gao; Heather Valentine; Ayon Nandi; Lorena Gapasin; Robert F Dannals; Andrew G Horti
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

4.  Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors.

Authors:  Yongjun Gao; Kenneth J Kellar; Robert P Yasuda; Thao Tran; Yingxian Xiao; Robert F Dannals; Andrew G Horti
Journal:  J Med Chem       Date:  2013-09-19       Impact factor: 7.446

5.  18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Yuchuan Wang; Sofya Abazyan; Robert P Yasuda; Thao Tran; Yingxian Xiao; Niaz Sahibzada; Daniel P Holt; Kenneth J Kellar; Mikhail V Pletnikov; Martin G Pomper; Dean F Wong; Robert F Dannals
Journal:  J Nucl Med       Date:  2014-02-20       Impact factor: 10.057

6.  In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys.

Authors:  Jun Toyohara; Kiichi Ishiwata; Muneyuki Sakata; Jin Wu; Shingo Nishiyama; Hideo Tsukada; Kenji Hashimoto
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

Review 7.  Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography.

Authors:  Andrew G Horti
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

8.  [11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys.

Authors:  Kenji Hashimoto; Shingo Nishiyama; Hiroyuki Ohba; Masaaki Matsuo; Tatsuhiko Kobashi; Makoto Takahagi; Masaomi Iyo; Takeru Kitashoji; Hideo Tsukada
Journal:  PLoS One       Date:  2008-09-18       Impact factor: 3.240

Review 9.  Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders.

Authors:  Hans O Kalkman; Dominik Feuerbach
Journal:  Cell Mol Life Sci       Date:  2016-03-15       Impact factor: 9.261

10.  An experimental study on (131)I-CHIBA-1001: a radioligand for α7 nicotinic acetylcholine receptors.

Authors:  Lei Yin; Qian Zhao; Ling Li; Su Lei Zhang; Xue Qi Chen; Chao Ma; Lei Kang; Meng Liu; Chun Li Zhang; Ping Yan; Rong Fu Wang
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.